

**HETA 2000-0341-2839**  
**Dallas Institute of Acupuncture and Oriental Medicine**  
**Dallas, Texas**

---

**Yvonne Boudreau, MD, MSPH**  
**Angela Weber, MS**

## PREFACE

The Hazard Evaluations and Technical Assistance Branch (HETAB) of the National Institute for Occupational Safety and Health (NIOSH) conducts field investigations of possible health hazards in the workplace. These investigations are conducted under the authority of Section 20(a)(6) of the Occupational Safety and Health (OSH) Act of 1970, 29 U.S.C. 669(a)(6) which authorizes the Secretary of Health and Human Services, following a written request from any employer or authorized representative of employees, to determine whether any substance normally found in the place of employment has potentially toxic effects in such concentrations as used or found.

HETAB also provides, upon request, technical and consultative assistance to Federal, State, and local agencies; labor; industry; and other groups or individuals to control occupational health hazards and to prevent related trauma and disease. Mention of company names or products does not constitute endorsement by NIOSH.

## ACKNOWLEDGMENTS AND AVAILABILITY OF REPORT

This report was prepared by Yvonne Boudreau, MD, MSPH and Angela Weber, MS of HETAB, Division of Surveillance, Hazard Evaluations and Field Studies (DSHEFS). Desktop publishing was performed by Nichole Herbert and Pat Lovell. Review and preparation for printing were performed by Penny Arthur.

Copies of this report have been sent to employee and management representatives at the Dallas Institute of Acupuncture and Oriental Medicine and the Occupational Safety and Health Administration Regional Office. This report is not copyrighted and may be freely reproduced. Single copies of this report will be available for a period of three years from the date of this report. To expedite your request, include a self-addressed mailing label along with your written request to:

NIOSH Publications Office  
4676 Columbia Parkway  
Cincinnati, Ohio 45226  
800-356-4674

After this time, copies may be purchased from the National Technical Information Service (NTIS) at 5825 Port Royal Road, Springfield, Virginia 22161. Information regarding the NTIS stock number may be obtained from the NIOSH Publications Office at the Cincinnati address.

**For the purpose of informing affected employees, copies of this report shall be posted by the employer in a prominent place accessible to the employees for a period of 30 calendar days.**

## Highlights of the NIOSH Health Hazard Evaluation of the Dallas Institute of Acupuncture and Oriental Medicine

Managers at the Dallas Institute of Acupuncture and Oriental Medicine (DIAOM) asked investigators from the National Institute for Occupational Safety and Health (NIOSH) to see if procedures at their clinic put employees at risk of exposure to certain pathogens. The primary pathogens of concern were the Hepatitis B and C viruses and the human immunodeficiency virus which are found in blood and body fluids.

### What NIOSH Did

- We met with managers and employees to discuss clinic policies and procedures.
- We performed a visual inspection of the clinic procedure rooms and offices.
- We observed acupuncture, moxibustion, and cupping procedures performed at the clinic.

### What NIOSH Found

- Sharps containers were generally not located within easy reach of the practitioner while treatments were being performed.
- The cupping jars, gauze, and gloves used by the practitioner were contaminated with blood during cupping procedures.
- The protective sheath around the acupuncture needles provides some protection from needlesticks. However, there is still a potential for needlesticks after the needle is removed from the patient's skin.
- An ozone generator is used to control odors from moxa smoke and other herbs.
- Latex and non-latex gloves are stored outside the treatment rooms and not within easy reach when needed.

### What the DIAOM Can Do

- Insist that employees report all exposures to blood or body fluids.
- Offer Hepatitis B vaccination to employees.
- Refer employees who have had blood or body fluid exposures to a physician who is familiar with bloodborne pathogen exposures.
- Reduce exposure to latex as much as possible by providing non-latex gloves or powder-free, low-protein gloves.
- Stop using ozone generators.
- Move gloves and sharps containers closer to the practitioner during procedures.

### What DIAOM Employees Can Do

- Report all blood exposures.
- As soon as possible after a blood exposure, see a physician who is familiar with bloodborne pathogen exposures.
- When using gloves, wear non-latex gloves whenever possible.
- Get the Hepatitis B vaccination.



*What To Do For More Information:  
We encourage you to read the full report. If you would like a copy, either ask your health and safety representative to make you a copy or call 1-513-841-4252 and ask for HETA Report # 2000-0341-2839*



**Health Hazard Evaluation Report 2000-0341-2839  
Dallas Institute of Acupuncture and Oriental Medicine  
Dallas, Texas  
April 2001**

**Yvonne Boudreau, MD, MSPH  
Angela Weber, MS**

---

---

## SUMMARY

In June 2000, the National Institute for Occupational Safety and Health (NIOSH) received a request from management personnel at the Dallas Institute of Acupuncture and Oriental Medicine (DIAOM) to evaluate the potential for occupational exposures to bloodborne pathogens (BBPs; e.g., the human immunodeficiency virus [HIV], Hepatitis B virus [HBV] and Hepatitis C virus [HCV]) from procedures performed at DIAOM. In response to this request, NIOSH investigators conducted a site visit in October 2000. During this visit, we met with management and employee representatives to discuss clinic policies and procedures; performed a visual inspection of the clinic procedure rooms and offices; and observed acupuncture, moxibustion, and cupping procedures.

Although there have been reports of acupuncture procedures resulting in patients becoming infected with HIV, HBV, and HCV, these incidents were, in most cases, related to exposure to improperly sterilized reusable needles. With the current standard practice of using single-use, sterile acupuncture needles, this risk is greatly decreased. However, there is still a potential risk to the acupuncture practitioner for BBP exposures from needles freshly removed from a patient's skin. Furthermore, the cupping procedure used at DIAOM extracts several milliliters of blood and the cupping jars, gauze, and gloves used by the practitioner can be contaminated with blood from this procedure, posing another potential risk for infection with BBPs. In addition, we noted that sharps containers and gloves were located beyond easy reach of the practitioner during treatments and an ozone generator was occasionally used in the clinic for odor control. We offer several recommendations for decreasing the risk of occupational exposures to the employees at DIAOM.

NIOSH investigators found that acupuncture and cupping procedures can expose employees to BBPs. All exposures to blood should be evaluated by a physician. Ozone generators and latex gloves used at the DIAOM have the potential to cause illness in susceptible employees. Exposure to ozone and latex should be minimized.

**Keywords:** SIC 8049 (Offices and Clinics of Health care Practitioners, Not Elsewhere Classified), acupuncture, bloodborne pathogens, BBP, Human Immunodeficiency Virus, HIV, Hepatitis B virus, HBV, Hepatitis C virus, HCV, cupping, moxa.

# TABLE OF CONTENTS

Preface .....	ii
Acknowledgments and Availability of Report .....	ii
Highlights of the NIOSH Health Hazard Evaluation .....	iii
Summary .....	iv
Introduction .....	1
Background .....	1
Acupuncture .....	1
Dallas Institute of Acupuncture & Oriental Medicine .....	1
Methods .....	2
Evaluation Criteria .....	2
Bloodborne Pathogens .....	2
Needlesticks and Sharps Injuries .....	3
Hepatitis B .....	3
Hepatitis C .....	4
Human Immunodeficiency Virus .....	4
Sterilization and Disinfection .....	5
Latex .....	5
Results .....	5
Discussion .....	6
Recommendations .....	6
References .....	7
Appendix A – Herbs and Tea Pills at DIAOM .....	13

## INTRODUCTION

In June 2000, the National Institute for Occupational Safety and Health (NIOSH) received a request from management personnel at the Dallas Institute of Acupuncture and Oriental Medicine (DIAOM) to evaluate the potential for occupational exposures to bloodborne pathogens (BBPs; e.g., the human immunodeficiency virus [HIV], Hepatitis B virus [HBV] and Hepatitis C virus [HCV]) from acupuncture and other procedures. In response to this request, NIOSH investigators conducted a site visit in October 2000.

## BACKGROUND

### Acupuncture

The Chinese tradition of acupuncture dates back at least 2000 years.<sup>1</sup> This practice gained attention in the United States (US) in 1972 when a New York Times reporter wrote about having received acupuncture while traveling with President Nixon in China.<sup>2</sup> In 1975, the first US acupuncture school (The New England School of Acupuncture) was opened in Watertown, Massachusetts. In 1982, the profession founded the Accreditation Commission for Colleges of Acupuncture and Oriental Medicine (ACAOM) which, in 1990, became recognized by the US Department of Education as an agency for accreditation at the master's degree level.<sup>3</sup> In 1997, the National Institutes of Health issued a consensus statement declaring acupuncture to be an effective treatment for certain medical conditions.<sup>4</sup> There are roughly 10,500 licensed acupuncturists in the US providing about 9-12 million patient visits annually. Most acupuncture practitioners are required to take board exams offered by the National Commission for the Certification of Acupuncture and Oriental Medicine (NCCAOM) to become certified practitioners.<sup>5</sup> Local acupuncture regulatory agencies may offer an additional certification process in certain states.

Acupuncture involves the insertion of very fine needles into the skin at specific points.<sup>6</sup> Other

procedures often used in conjunction with acupuncture include *moxibustion*, which involves the burning of moxa (Latin name: *Artemesia vulgaris*; also called “mugwort” and “wild chrysanthemum”),<sup>7</sup> and *cupping*, in which a lancet is used to puncture the skin, after which a small glass jar is heated and placed over the punctured area, creating a vacuum that draws out approximately three to five milliliters (mL) of blood.<sup>8</sup> Transfer of viral infections, including HIV, HBV, and HCV, may occur between patients or from patients to practitioners if needles are not properly sterilized between uses.<sup>9,10,11,12,13,14</sup> However, sterile, single-use needles are almost universally used in the US today and are regulated by the US Food and Drug Administration (FDA) as approved medical devices.<sup>15</sup> The needles are surrounded by a protective plastic sheath, or guide tube, that prevents the needle from being inserted too deeply into the skin. This sheath also helps prevent inadvertent needlesticks to the practitioner. Many herbal products are used by acupuncture practitioners to treat a variety of patient concerns. These are classified by the FDA as dietary supplements and as such are not subject to the strict regulations required for compounds classified as drugs.<sup>16</sup>

### Dallas Institute of Acupuncture & Oriental Medicine

Practitioners at the DIAOM have been offering acupuncture and other Oriental medicine procedures since 1996. They maintain a staff of approximately 14 faculty and 60 students who provide care to approximately 25 clients per week. All students must complete a clean needle technique course prior to beginning their training at the DIAOM. This course is sponsored by the Council of Colleges of Acupuncture and Oriental Medicine (CCAOM),<sup>17</sup> and its content is based on recommendations from the Centers for Disease Control and Prevention (CDC) regarding preventing transmission of BBPs.<sup>18</sup> Neither students nor faculty are required to receive a medical exam or any vaccinations to work at the DIAOM. If they sustain a needlestick or other

sharp object injury, they are sent to a physician for evaluation.

Solid-bore, individually packaged, 28-38 gauge single-use needles are utilized for acupuncture procedures. Needles, gauze, and cotton that have been contaminated with blood or other body fluids are disposed of into sharps containers located in each treatment room. Tweezers, forceps, and other reusable devices are soaked in a bleach solution between uses. Latex and non-latex gloves are available for all practitioners, and their use is encouraged but not mandatory. The gloves are stored in a supply room outside of the treatment rooms. All surfaces in the treatment rooms are cleaned with a 3% hydrogen peroxide solution between patient treatments.

The DIAOM maintains a collection of over 300 Oriental herbs and pills in a room within their office facility (Appendix A). These products are imported from China and, because they are classified as “dietary supplements” (not as “drugs”), they are not subject to any routine regulatory oversight in the US.<sup>16</sup> Specific herbs and/or pills are selected for treatment of a client’s illness and then may be burned, ground with a mortar and pestle, or used in their original form. An ozone (O<sub>3</sub>) generator is occasionally used for the purpose of controlling odors.

## METHODS

During the site visit, NIOSH investigators met with management and employee representatives to discuss clinic policies and procedures, performed a visual inspection of the clinic procedure rooms and offices, and observed acupuncture, moxibustion, and cupping procedures utilized at the clinic.

## EVALUATION CRITERIA

### Bloodborne Pathogens

In the health care setting, BBP transmission can occur when health care workers (HCWs) are exposed to the blood or body fluids of infected patients.<sup>19</sup> Occupational exposures that may result in HIV, HBV, or HCV transmission include needlestick and other sharps injuries; direct inoculation of a virus into scratches, lesions, abrasions, or burns on the skin (percutaneous); and inoculation of virus onto the mucosal (mucous membrane) surfaces of the eyes, nose or mouth through splashes. HIV, HBV, and HCV do not spontaneously penetrate intact skin, and airborne transmission of these viruses does not occur.

In 1987, CDC developed universal precautions to help protect HCWs and patients from infection with BBPs in the health care setting.<sup>20</sup> These recommendations stress that blood is the most important source of HIV, HBV, and other BBPs and that infection control efforts should focus on the prevention of exposures to blood and the use of available vaccines. In 1991, the Occupational Safety and Health Administration (OSHA) issued the BBP Standard.<sup>21</sup> It requires that (a) HBV vaccine be made available to HCWs who are at risk of occupational HBV exposure, (b) written exposure control plans be developed, (c) engineering and work practice exposure controls be implemented, and (d) HCWs receive annual training in BBP exposure prevention. In 1995, CDC introduced the concept of standard precautions emphasizing that blood and body fluids of *all* patients should be considered potentially infectious.<sup>20,22,23</sup> The core elements of standard precautions comprise hand washing after patient contact, the use of barrier precautions (e.g., gloves, gowns, goggles, and face shields) to prevent mucocutaneous contact, minimal manual manipulation of sharp instruments and devices, and disposal of these items in puncture-resistant containers.

### Needlesticks and Sharps Injuries

On November 6, 2000, the Needlestick Safety and Prevention Act (NSPA) became public law.<sup>24</sup> This Act mandates specific revisions to OSHA’s

BBP Standard<sup>21</sup> in accordance with specific language included in the NSPA. These revisions include a requirement that in workplaces where there is a risk for percutaneous exposures to blood or other body fluids, a sharps injury log be kept in addition to the OSHA Log and Summary of Occupational Injuries and Illnesses (Form 200). This sharps injury log must include detailed information on the injury, including the type and brand of device involved in the incident, the department or work area where the exposure incident occurred, and an explanation of how the incident occurred.

## **Hepatitis B**

Persons infected with HBV are at risk for chronic liver disease (e.g., chronic active Hepatitis, cirrhosis, and primary hepatocellular carcinoma) and can potentially infect others. The probability of HBV transmission after an occupational exposure is dependent upon the concentration of the virus in the implicated body fluid, the volume of infective material transferred, and the route of inoculation (e.g., percutaneous or mucosal). One of the most common modes of HBV transmission in the health care setting is an unintentional injury from a needle contaminated with blood from a patient who is Hepatitis B surface antigen (HBsAg) positive.<sup>25</sup> The risk of transmission after a needlestick exposure, if the exposed person is not immune, is about 30% if the source patient is positive for Hepatitis B e antigen (HBeAg).<sup>26,27</sup>

The incidence of HBV infection among HCWs has decreased since the early 1980s.<sup>28</sup> The decline is attributed to the implementation of standard precautions in health care settings, including the increasing use of barrier precautions and personal protective devices (gloves, goggles, etc.) and increasing levels of Hepatitis B vaccination coverage among HCWs.<sup>29,30,31</sup> The Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC) recommend that workers potentially exposed to blood or blood-contaminated body fluids receive vaccination with the HBV vaccine, which provides pre- and post-exposure protection against HBV infection.<sup>32,33</sup> Three intramuscular

doses induce a protective antibody response in >90% of healthy recipients for at least 12 years, and routine booster doses of Hepatitis B vaccine are not considered necessary.<sup>34,35,36</sup> One to two months after completion of the three-dose series, post-vaccination testing should be done for all HCWs who are at risk for BBP exposures. Persons who do not show the presence of antibodies to HBV after the primary vaccine series should complete a second three-dose vaccine series or be evaluated to determine if they are HBsAg positive. Re-vaccinated persons should be retested at the completion of the second vaccine series. Non-responders who are HBsAg negative should be considered susceptible to HBV infection and should be counseled regarding precautions to prevent HBV infection and the need to obtain Hepatitis B immune globulin (HBIG) prophylaxis for any known or probable exposure to HBsAg-positive blood.<sup>20</sup> For exposed persons who are not immune, either because they have not received the HBV vaccine series or because they are non-responders, multiple doses of HBIG have been shown to provide an estimated 75% protection from HBV infection following percutaneous exposure to HBsAg-positive blood when initiated within one week of exposure.<sup>37,38,39</sup> These individuals should also receive the HBV vaccine series.<sup>40</sup>

HBV is resistant to drying, simple detergents, and alcohol, and has been found to be stable on environmental surfaces for at least seven days.<sup>41,42,43,44,45,46</sup> Thus, indirect inoculation can occur via inanimate objects (e.g., contaminated medical equipment or environmental surfaces). However, HBV has been shown to be inactivated by several intermediate-level disinfectants, including 0.1% glutaraldehyde and 500 parts per million (ppm) free chlorine from sodium hypochlorite (i.e., household bleach).<sup>47,48</sup> Heating to 98°C for two minutes also inactivates HBV.<sup>49</sup>

## **Hepatitis C**

HCV was identified in 1988 as the primary cause of non-A, non-B Hepatitis, and as a major cause of acute and chronic Hepatitis worldwide. HCV typically circulates at lower titers in infected blood than HBV and is not transmitted efficiently through occupational exposures to blood.<sup>50,51</sup>



Hence, HCV is most likely to be transmitted only by *large* exposures to blood, such as through the transfusion of blood or blood products from infectious donors or sharing of contaminated needles among injection drug users.<sup>19</sup> The actual risk of infectivity has not been well-defined for HCV. The average incidence of HCV infection after needlestick or sharps exposure from a known HCV-positive source patient ranges from 0 to 7%, with one study reporting that transmission occurred only from hollow-bore needles compared with other sharps.<sup>51,52,53,54,55</sup> No transmission to HCWs has been documented from intact or non-intact skin exposures to blood.<sup>51</sup> The risk for transmission after exposure to fluids or tissues other than blood has not been quantified, but is expected to be low.<sup>40</sup>

There is currently no vaccine available for HCV, and post-exposure prophylaxis with immune globulin does not appear to be effective in preventing HCV infection.<sup>56</sup> Even in the absence of available pre- or post-exposure prophylaxis, individual worksites should establish policies and procedures for follow-up after percutaneous or mucosal exposure to anti-HCV positive blood to address individual worker's concerns about their risk and outcome.<sup>57</sup> The HCV status of the source and the exposed person should be determined and, if indicated, follow-up HCV testing should be performed to determine if infection develops in the exposed worker.<sup>50</sup>

Data are limited on survival of HCV in the environment. Rapid degradation of HCV occurs when serum containing HCV is left at room temperature.<sup>58</sup> In contrast to HBV, the data suggest that environmental contamination with blood containing HCV does not pose a significant risk for transmission in the health care setting, with the possible exception of the hemodialysis setting where HCV transmission related to environmental contamination and poor infection control practices has been implicated.<sup>59,60,61,62,63,64</sup>

## **Human Immunodeficiency Virus**

Most occupational exposures to HIV do not result in infection. The risk of infection varies with the type of exposure and factors such as the amount

of blood involved in the exposure, the amount of virus in the blood, and whether treatment was given after the exposure. Among HCWs, the average risk of HIV infection after a needlestick or cut exposure to HIV-infected blood from freshly contaminated sharps is 0.3% (about 1 in 300).<sup>65</sup> Stated another way, 99.7% of needlestick/cut exposures do not result in infection. The risk of HIV infection after exposure of the eye, nose, or mouth to HIV-infected blood is estimated to be 0.09% (about 1 in 1000).<sup>66</sup> There have been no documented cases of HIV transmission due to an exposure involving a small amount of blood on intact skin. Although episodes of HIV transmission after non-intact skin exposure have been documented, the average risk for transmission by this route is estimated to be less than the risk for mucous membrane exposures.<sup>67,68</sup> The risk for transmission after exposure to fluids or tissues other than HIV-infected blood also has not been quantified, but appears to be considerably lower than for blood exposures.<sup>69</sup>

After an occupational exposure to HIV, employees should be tested for HIV status, and if not positive, should be followed-up for up to six months. Post-exposure prophylaxis is an important element in the management of an occupational exposure to HIV.<sup>70</sup> The use of zidovudine (ZDV) and other antiviral drugs after certain occupational exposures may reduce the chance of HIV infection.<sup>71</sup> A physician familiar with the risks of HIV infection and the side effects of the drugs should be consulted immediately after an exposure to determine whether post-exposure treatment is appropriate and, if so, the selection of the regimen to use. Prevention of occupational exposures, particularly percutaneous injuries, is the primary means of avoiding occupationally acquired HIV infection.

Studies have indicated that HIV is readily susceptible to a variety of disinfectants.<sup>72</sup> The titer of HIV in blood is reduced by 90-99% within several hours after drying, and it further diminishes with time.<sup>20,73</sup> There is no evidence for HIV transmission from environmental surfaces.

## Sterilization and Disinfection

Standard sterilization and disinfection procedures recommended for patient care equipment are adequate to sterilize or disinfect items contaminated with blood or other body fluids from people infected with BBPs.<sup>20</sup> Because foreign material may interfere with the sterilization or disinfection procedure, devices must first be adequately cleaned.<sup>74</sup> All spills of blood and blood-contaminated body fluids should be promptly cleaned by a person wearing appropriate gloves and using an Environmental Protection Agency-approved disinfectant or a 1:10 to 1:100 solution of household bleach.<sup>20</sup> Visible material should first be removed with disposable towels or other means to prevent direct contact with blood. The area should then be decontaminated with an appropriate disinfectant.<sup>20</sup>

## Latex

Natural latex is an intracellular milky fluid produced by the laticifer cells of the tropical rubber tree, *Hevea brasiliensis*. It is manually harvested and, through multiple processes, is converted into natural rubber latex (NRL). This, in turn, is used for the manufacture of commercial latex products, including latex gloves, balloons, and condoms. Over the last 20 years, reports of adverse reactions to NRL have increased, and latex allergy has been recognized as an occupational health hazard. Studies in HCWs have shown latex allergy prevalence rates of 2-16.9%.<sup>75,76,77</sup> Several reasons may exist for the increase in reports of latex allergy and other adverse reactions to latex. The use of latex gloves has increased significantly since the introduction of universal precautions to prevent the transmission of HIV, HBV, and other infectious agents. To meet the increased demand for latex gloves, some manufacturers may produce more allergenic gloves because of changes in raw materials, processing, or manufacturing procedures. Also, physician and public awareness of latex allergy has increased. Routes of exposure to NRL include dermal, mucosal, percutaneous, and inhalation. NRL

sensitization is also associated with allergies to certain foods, including banana, avocado, potato, tomato, passion fruit, kiwi fruit, papaya, and chestnut.<sup>78,79</sup> The prevention of adverse latex reactions depends on the identification of individuals who are allergic so that they can avoid exposure to NRL-containing products. If latex allergy is suspected, a physician familiar with latex allergy should be consulted.

## RESULTS

During our observation of procedures at the DIAOM, we noted the following:

1. Sharps containers were generally located in a corner of the treatment rooms beyond easy reach of the practitioner while treatments were being performed. Approximately 30 pounds of sharps containers are disposed of as biohazardous waste on a monthly basis.
2. Three to five mL of blood were extracted during the cupping procedures. The cupping jars, gauze, and gloves used by the practitioner were contaminated with blood from this procedure. Contaminated cupping jars are placed on a tray covered with a reusable, absorbent liner. The potential for cross-contamination exists if this liner cannot be appropriately decontaminated. Decontamination procedures were not observed during the NIOSH site visit, but the DIAOM management told us that they planned to replace the liners with a disposable adsorbent product.
3. The protective sheath around the acupuncture needles provides some protection from unintentional needlesticks. However, there is still a potential for needlesticks after the needle is removed from the patient's skin.
4. The burning of moxa created a noticeable, strong odor and visible smoke in the treatment room. DIAOM personnel reported that a smokeless form of moxa is available.
5. Gloves are stored outside of treatment rooms; none were available in the individual treatment rooms.

6. An O<sub>3</sub> generator is occasionally used for the purpose of controlling odors. The O<sub>3</sub> generator was not used during the NIOSH site visit.

7. There is no exhaust ventilation or containment provided in the herbal storage room where the herbs and other products are prepared (i.e., crushed or mixed).

## DISCUSSION

Although the practice of acupuncture has historically resulted in HIV, HBV, and HCV infections in patients, these incidents were, in most cases, related to the utilization of reusable needles that were not properly sterilized.<sup>9-14</sup> With the incorporation of single-use, sterile acupuncture needles, this risk is greatly decreased. However, there is still a potential risk to the acupuncture practitioner of exposures from needles freshly removed from a patient's skin. In addition, the cupping procedure used at DIAOM produces several milliliters of blood, and exposure to this blood is a potential risk for infection with any of the BBPs. O<sub>3</sub> generators (electronic devices that emit O<sub>3</sub> by design) are commercially available and widely promoted as air cleaning devices that eliminate chemical pollutants, remove indoor allergens, kill molds and bacteria, and "freshen air" in the indoor environment. However, no carefully conducted studies (published in the peer-reviewed literature) have substantiated that O<sub>3</sub> removes these pollutants innocuously.<sup>80,81</sup> In fact, studies have found that in addition to being a primary pulmonary irritant, O<sub>3</sub> can react with other chemicals in the indoor environment to create insidious and more irritating chemical compounds.<sup>82,83</sup>

## RECOMMENDATIONS

1. Immediately following an exposure to blood or body fluids, or to objects potentially contaminated with blood or body fluids, the following should occur: areas of skin exposed to needlesticks and cuts should be washed with soap and water; after splashes to the nose, mouth, or skin, the area should be flushed with water; and after splashes to the eyes, the eyes should be

irrigated with clean water, saline, or sterile irrigants.<sup>23</sup>

2. All workplace needlesticks, cuts from other sharp objects, or splashes onto the skin, eyes, nose, or mouth should be immediately reported and evaluated by a physician familiar with occupational BBP exposures. A program should be put into place that emphasizes and ensures that this reporting and medical follow-up is taking place.<sup>21, 84</sup>

3. In accordance with CDC recommendations and OSHA requirements for HCWs, all employees should be offered the HBV vaccine free of charge.<sup>32,85</sup> One to two months after completion of the three-dose vaccination series, employees should be tested for antibody to Hepatitis B surface antigen (anti-HBs). Booster doses of Hepatitis B vaccine are not considered necessary, and periodic serologic testing to monitor antibody concentrations after completion of the vaccine series is not recommended.

4. Employers should provide education to employees regarding the prevention of HCV in the occupational setting, and such information should be routinely updated to ensure accuracy.<sup>57</sup> The DIAOM should establish policies and procedures for follow-up after percutaneous or mucosal exposure to anti-HCV positive blood to address individual worker's concerns about their risk and outcome.

5. A sharps injury log should be kept in accordance with the 2000 NSPA.<sup>24</sup>

6. Employees should be provided with accurate and up-to-date information on the risk and prevention of infection from all bloodborne pathogens. After any sharp injury or splash to the eyes, nose, or mouth, DIAOM management should refer the exposed worker to an occupational or infectious disease physician to discuss the need for post-exposure treatment and follow-up.<sup>40</sup>

7. Consider placing the sharps containers on movable carts that can be placed near the practitioner during procedures to decrease the

handling time of contaminated gauze, cotton, and acupuncture needles.

8. Because of the potential for employees to develop allergy to latex, the use of latex gloves should be limited to those situations where latex is considered necessary to prevent skin exposure to infectious agents. If latex gloves are chosen, use powder-free low-protein gloves. Consider making gloves available in treatment rooms so that practitioners will have easy access to them during procedures.

9. All spills of blood and blood-contaminated body fluids should be promptly cleaned by a person wearing appropriate gloves and using an Environmental Protection Agency-approved disinfectant or a 1:10 to 1:100 solution of household bleach.<sup>20,40</sup> Visible material should first be removed with disposable towels or other means to prevent direct contact with blood. The area should then be decontaminated with an appropriate disinfectant. Latex gloves do not provide adequate protection from disinfection agents, since the chemicals may cause deterioration of the glove material. Consideration should be given to using vinyl or nitrile rubber gloves instead of latex. Nitrile, for example, could safely be used with most disinfectants including ethyl alcohol, hydrogen peroxide, glutaraldehyde, and sodium hypochlorite (bleach).<sup>86</sup> Nitrile also offers adequate protection from bodily fluids.

10. The use of O<sub>3</sub> generators should be avoided. If an ozone generator is used, employees need to be informed of ozone exposures as part of the OSHA Hazard Communication Standard or Worker Right-to-Know regulations.<sup>87</sup> Source control, dilution ventilation, proper filtration, and prudent mechanical hygiene practices are far more effective alternatives to managing and alleviating indoor environmental pollutants than use of O<sub>3</sub> generators.

11. The use of source control ventilation should be considered when dust-producing (e.g., crushing) activities are performed. Additionally, since a smokeless version of moxa is available, consider its use where feasible.

## REFERENCES

1. Birch, SJ, Felt RL [1999]. Understanding Acupuncture. Brookline, Massachusetts: Paradigm Publications.
2. Cenicerros S, Brown GR [1998]. Acupuncture: a review of its history, theories, and indications. *South Med J* 91(12):1121-5.
3. Department of Education, Office of Postsecondary Education [1995]. Nationally Recognized Accrediting Agencies and Associations. Criteria and Procedures for Listing by the US Secretary For Education and Current List. Washington, DC, US Department of Education.
4. National Institutes of Health [1997]. NIH Consensus Statement: acupuncture. 15(5):1-34. <http://odp.od.nih.gov/consensus/cons/107/107statement.htm>.
5. Council of Colleges of Acupuncture and Oriental Medicine. Spring 2000 Newsletter. [http://www.ccaom.org/spring\\_2000.htm](http://www.ccaom.org/spring_2000.htm).
6. Firebrace P [1988]. Acupuncture: restoring the Body's Natural Healing Energy. New York, New York: Harmony Books.
7. Therapeutics of Acupuncture & Moxibustion: English-Chinese Encyclopedia of Practical Therapeutic Chinese Medicine [1991]. Xu Xiangcai (Ed). Hong Kong: Higher Education Press.
8. Chirali, IZ [1999]. Cupping Therapy: Traditional Chinese Medicine. London, UK: Churchill Livingstone.
9. Peuker ET, White A, Ernst E, Pera F, Filler TJ [1999]. Traumatic complications of acupuncture. *Arch Fam Med* 8:553-558.

10. Kent GP, Brondum J, Keenlyside RA, LaFazia LM & Scott HD [1988]. A large outbreak of acupuncture-associated Hepatitis B. *Am J Epidemiol* 127:591-8.
11. Vittecoq D, Mettetal JF, et al. [1989]. Acute HIV infection after acupuncture treatments. *NEJM* 320:250-1.
12. Stryker WS, Gunn RA, Francis DP [1986]. Outbreak of Hepatitis B associated with acupuncture. *J Fam Pract* 22(2):155-8.
13. Sun CA, Chen HC, Lu CF, et al. [1999]. Transmission of Hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. *J Med Virol* 59(3):290-6.
14. Phoon WO, Fong NP, Lee J [1988]. History of blood transfusion, tattooing, acupuncture and risk of Hepatitis B surface antigenemia among Chinese men in Singapore. *Am J Pub Hlth* 78:958-60.
15. Department of Health and Human Services, Food and Drug Administration [1996]. 21 CFR Part 880 [Docket Number 94P-0443], Medical Devices: reclassification of acupuncture needles for the practice of acupuncture, final rule. *Federal Register* 61(236):64616-7.
16. US Food and Drug Administration [1999]. FDA Consumer Publication No. FDA 99-2323.
17. Council of Colleges of Acupuncture and Oriental Medicine [2001]. <http://www.ccaom.org/>.
18. Clean Needle Technique Manual for Acupuncturists: guidelines and standards for the clean and safe clinical practice of acupuncture [1997]. Fourth Ed. National Acupuncture Foundation.
19. Beltrami EM, Williams IT, Shapiro CN & Chamberland ME [2000]. Risk and Management of Bloodborne Infections in Health Care Workers. *Clin Microbiol Rev* July 2000:385-407.
20. Centers for Disease Control & Prevention [1987]. Recommendations for prevention of HIV transmission in health-care settings. *MMWR* 36(2S):1-18.
21. US Department of Labor, Occupational Safety and Health Administration [1991]. 29 CFR Part 1910.1030. Occupational exposure to bloodborne pathogens: final rule. *Fed Regist* 56:64004-182.
22. Garner JS & the Hospital Infection Control Practices Advisory Committee [1996]. Guidelines for isolation precautions in hospitals. *Inf Cont Hosp Epi* 17:53-80.
23. Centers for Disease Control [1988]. Update: universal precautions for prevention of transmission of HIV, HBV & other bloodborne pathogens in health-care settings. *MMWR* 37:377-82, 387-8.
24. United States Congress [2000]. Public Law 106-430. Needlestick Safety and Prevention Act. HR5178.
25. Alter HJ, Seell LB, Kaplan PM, McAuliffe VJ, et al. [1976]. Type B Hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. *NEJM* 295:909-13.
26. Grady GF, Lee VA, Prince AM, et al. [1978]. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. *J Inf Dis* 138:625-38.
27. Werner BG & Grady GF [1982]. Accidental Hepatitis B surface antigen positive inoculations: use of e antigen to estimate infectivity. *Ann Intern Med* 97:367-9.

28. Centers for Disease Control & Prevention [1994]. Hepatitis surv. report, Atlanta. p. 3-6.
29. Beckman SE, Vlahow F, Koziol DE, et al. [1994]. Temporal association between implementation of universal precautions and a sustained progressive decrease in percutaneous exposures to blood. *Clin Inf Dis* 18:562-9.
30. Haiduven DJ, Domain TM, Stevens DA [1992]. A five-year study of needlestick injuries: significant reduction associated with communication, education and convenient placement of sharps containers. *Inf Cont Hosp Epi* 13:265-71.
31. Wong ES, Stotka JL, Chinchilli DS, et al. [1991]. Are universal precautions effective in reducing the number of occupational exposures among health care workers? A prospective study of physicians on a medical service. *JAMA* 265:1123-8.
32. Centers for Disease Control & Prevention [1997]. Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 46:RR-18, December 26.
33. Centers for Disease Control [1982]. Recommendation of the Immunization Practices Advisory Committee (ACIP) - inactivated Hepatitis B virus vaccine. *MMWR* 31:317-28.
34. Wainwright RB, McMahon BJ, Bulkow LR, et al. [1989]. Duration of immunogenicity and efficacy of Hepatitis B vaccine in a Yupik Eskimo population. *JAMA* 261:2362-6.
35. West DJ, Watson B, Lichtman J, et al. [1994]. Persistence of immunologic memory for twelve years in children given Hepatitis B vaccine in infancy. *Pediatr Inf Dis J* 13:745-7.
36. Whittle HC, Maine J, Pilkington M, et al. [1995]. Long-term efficacy of continuing Hepatitis B vaccination in infancy in two Gambian villages. *Lancet* 345:1089-92.
37. Grady GF, Lee VA, Prince AM, et al. [1978]. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. *J Inf Dis* 138:625-38.
38. Seeff LB, Zimmerman HJ, Wright EC, et al. [1977]. A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion Hepatitis: a Veterans' Administration cooperative study. *Gastroenterology* 72:11-21.
39. Prince AM, Szmuness W, Mann MK, et al. [1975]. Hepatitis B "Immune" globulin: effectiveness in prevention of dialysis-associated Hepatitis. *NEJM* 293:1063-7.
40. Centers for Disease Control & Prevention [2001]. Updated Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV and HIV and Recommendations for Postexposure Prophylaxis (PEP). Preliminary draft, March, 2001.
41. Favero MS [1985]. Sterilization, disinfection and antisepsis in the hospital, p. 129-37. In Lennette EH, Balows A, Hausler WJ & Shadomy HJ (eds.). *Manual of clinical microbiology*, 4<sup>th</sup> ed. American Society for Microbiology, Washington, DC.
42. Pattison CP, Boyer KM, Maynard JE & Kelly PC [1974]. Epidemic Hepatitis in a clinical laboratory: possible association with computer card handling. *JAMA* 230:854-7.
43. Bond WW, Favero MS, Peterson NJ, et al. [1981]. Survival of Hepatitis B virus after drying and storage for one week [Letter]. *Lancet* 1:550-1.
44. Hennekens CH [1973]. Hemodialysis-associated Hepatitis: an outbreak among hospital

personnel. *JAMA* 225:407-8.

45. Garibaldi RA, Forrest JN, Bryan JA, et al. [1973]. Hemodialysis-associated Hepatitis. *JAMA* 225:384-9.

46. Snyderman DR, Bryan JA, Macon EJ, Gregg MB [1976]. Hemodialysis-associated Hepatitis: a report of an epidemic with further evidence on mechanisms of transmission. *Am J Epi* 104:563-70.

47. Bond WW, Favero MS, Peterson NJ & Ebert JW [1983]. Inactivation of Hepatitis B virus by intermediate-to-high-level disinfectant chemicals. *J Clin Micro* 18:535-8.

48. Favero MS & Bond WW [1993]. Disinfection and sterilization, p. 565-75. In Zuckerman AJ & Thomas HC (eds.). *Viral Hepatitis; scientific basis and clinical management*. Churchill Livingstone, New York, NY.

49. Kubayashi H, Tsuzuki M, Koshimizu K, et al. [1984]. Susceptibility of Hepatitis B virus to disinfectants and heat. *J Clin Microbiol* 20:214-6.

50. Bradley DW, Krawczynski K, Beach MJ & Purdy MA [1991]. Non-A, non-B Hepatitis: toward the discovery of Hepatitis C & E viruses. *Semin Liver Dis* 11:128-46.

51. Davis GL & Lau JYN [1995]. Hepatitis C. p. 2082-114. In WS Haubrich, F Schaffner & JE Berk (eds), *Gastroenterology*, 5<sup>th</sup> ed. WB Saunders & Co., Philadelphia, PA.

52. Alter MJ [1997]. The epidemiology of acute and chronic Hepatitis C. *Clin Liver Dis* 1:559-68.

53. Lanphear BP, Linnemann CC, Jr., Cannon CG, et al. [1994]. Hepatitis C virus infection in health care workers: risk of exposure and infection. *Inf Cont Hosp Epi* 15:745-50.

54. Puro V, Petrosillo N, Ippolito G, Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Risk of Hepatitis C seroconversion after occupational exposure in health care workers. *Am J Inf Cont* 23:273-7.

55. Mitsui T, Iwano K, Masuko K, et al. [1992]. Hepatitis C virus infection in medical personnel after needlestick accident. *Hepatology* 16:1109-14.

56. Alter MJ [1994]. Occupational exposure to Hepatitis C virus: a dilemma. *Inf Cont Hosp Epi* 15:742-44.

57. Centers for Disease Control & Prevention [1998]. Recommendations for the prevention and control of Hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR* 47(RR-19):1-39.

58. Cuypers HT, Bresters MD, Winkel IN, et al. [1992]. Storage conditions of blood samples and primer selection affect yield of cDNA polymerase chain reaction products of Hepatitis C virus. *J Clin Microbiol* 30:3320-4.

59. Davis GL, Lau JY, Urdea MS, et al. [1994]. Quantitative detection of Hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. *Hepatology* 19:1337-41.

60. Polish LB, Tong MJ, Co RL, Coleman PJ, Alter MJ [1993]. Risk factors for Hepatitis C virus infection among health care personnel in a community hospital. *Am J Inf Cont* 21:196-200.

61. Niu MT, Coleman PJ, Alter MJ [1993]. Multicenter study of Hepatitis C virus infection in chronic hemodialysis patients and staff. *Am J Kidney Dis* 22:568-73.

62. Hardy NM, Sandroni S, Danielson S, Wilson WJ [1992]. Antibody to Hepatitis C virus increases with time on hemodialysis. *Clin*

Nephrol 38:44-8.

63. Niu MT, Alter MJ, Kristensen C, Margolis HS [1992]. Outbreak of hemodialysis-associated non-A, non-B Hepatitis and correlation with antibody to Hepatitis C virus. *Am J Kidney Dis* 4:345-52.

64. Favero MS, Alter MJ [1996]. The reemergence of Hepatitis B virus infection in hemodialysis centers. *Sem Dialysis* 9:373-4.

65. Bell DM [1997]. Occupational risk of human immunodeficiency virus infection in health care workers; an overview. *Am J Med* 102(Suppl. 5B):9-14.

66. Ippolito GV, Puro G, et. al. [1993]. The risk of occupational human immunodeficiency virus infections in health care workers. *Arch Int Med* 153:1451-58.

67. Centers for Disease Control [1987]. Update: human immunodeficiency virus infections in health-care workers exposed to blood of infected patients. *MMWR* 36:285-89.

68. Fahey BJ, Koziol De, Banks SM, Henderson DK [1991]. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training. *Am J Med* 90:145-53.

69. Henderson DK, Fahey BJ, Willy M, et al. [1990]. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures: a prospective evaluation. *Ann Int Med* 113:740-46.

70. Centers for Disease Control & Prevention [1998]. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. *MMWR* 47(RR-7):1-34.

71. Cardo DM, Culver DH, et al. [1997] A case-control study of HIV seroconversion in health

care workers after percutaneous exposure. *NEJM* 337:1485-90.

72. Sattar SA & Springthorpe VS [1991]. Survival and disinfectant inactivation of the human immunodeficiency virus. *Rev Inf Dis* 13:430-47.

73. Van Bueren J, Simpson RA, Jacobs P & Cookson BD [1994]. Survival of human immunodeficiency virus in suspension and dried onto surfaces. *J Clin Microbiol* 32:571-74.

74. Martin MA, Reichelderfer M, and the Association for Professionals in Infection Control and Epidemiology, Inc. [1994]. APIC guideline for infection prevention and control in flexible endoscopy. *Am J Inf Cont* 22:19-38.

75. Arellano R, Bradley J, Sussman G. Prevalence of latex sensitization among hospital physicians occupationally exposed to latex gloves. *Anesthesiology* 77: 905-908, 1992.

76. Wrangsjö K, Osterman K, van Hage-Hamsten M. Glove-related skin symptoms among operating theatre and dental care unit personnel. II. Clinical examination, tests and laboratory findings indicating latex allergy. *Contact Dermatitis* 30: 139-143, 1994.

77. Yassin MS, Lierl MB, Fisher TJ, O'Brien K, Cross J, Steinmetz C. Latex allergy in hospital employees. *Annals of Allergy* 72: 245-249, 1994.

78. Blanco C, Carrillo T, Castillo R, Quiralte J, Cuevas M. Latex allergy: clinical features and cross-reactivity with fruits. *Ann Allergy* 73: 309-314, 1994.

79. Beezhold DH, Sussman GL, Liss GM, Chang M. Latex allergy can induce clinical reaction to specific foods. *Clin Exp Allergy* 26: 416-422, 1996.

80. Boeniger M [1995]. Use of Ozone Generating Devices to Improve Indoor Air



Quality. Am Ind Hyg J 56 June:590-8.

81. Shaughnessy RJ, Oatman L [1991]. The Use of Ozone Generators for Control of Indoor Air Contaminants in an Occupied Environment. Proceedings of ASHRAE Conference IAQ 91. Healthy Buildings. ASHRAE, Atlanta, GA.

82. Weschler CJ, Shields H [1997]. Potential Reactions among Indoor Pollutants. Atmospheric Environment 31(21):3487-95.

83. Zhang J & Liou P [1994]. Ozone in Residential Air: Concentrations, I/O Ratios, Indoor Chemistry and Exposures. Indoor Air 4:95-102.

84. Centers for Disease Control [1990]. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 39(RR-1):1-14.

85. Kopfer AM, McGovern PM. 1993. Transmission of HIV via a needlestick injury: practice recommendations and research implications. AAOHN Journal 41(8):374-81.

86. Forsberg K and Mansdorf SZ, eds [1997]. Quick selection guide to chemical protective clothing. 3<sup>rd</sup> ed. New York:Van Nostrand Reinhold.

87. Esswein EJ & Boeniger M [1994]. Effect of an Ozone Generating Air-Purifying Device on Reducing Concentrations of Formaldehyde in Air. App Occ Env Hyg 9(2):139-46.

## Appendix A – Herbs and Tea Pills at DIAOM

### Raw Herbs

Ai Ye	Da Fu Pi	Hai Zao	Lu Rang
Ai Ye Tan	Da Huang	Han Fang Ji	Luo Bu Ma
Ba Dou	Da Ji	Han Lian Cao	Luo Shi Teng
Bai Bu	Da Qing Ye	He Huan Pi	Ma Chi Xian
Bai Dou Kou	Dai Zhe Shi	He Shou Wu	Ma Huang
Bai Fu Zi	Dan Shen	He Ye	Ma Huang Gen
Bai Guo	Dan Zhu Ye	He Zi	Mai Meng Dong
Bai He	Dang Gui Pian	Hei Zhi Ma	Mai Ya
Bai Hua She She Cao	Dang Gui Wei	Hong Hua	Man Jing Zi
Bai Ji	Dang Shen	Hong Ling Zhi	Mang Xiao
Bai Ji Li	Deng Xin Cao	Hou Po	Mao Dong Qing
Bai Ji Tian	Di Fu Zi	Hu Gu	Ming Fan
Bai Jiang Cao	Di Gu Pi	Hu Huang Lian	Ma Yao
Bai Jie Zi	Di Huang (sheng)	Hu Jiao	Mu Dan Pi
Bai Mao Gen	Di Long	Hu Zhang	Mu Gua
Bai Qian	Di Yu	Hua Shi	Mu Li
Bai Shao Yao	Dong Gua Ren	Hua Zhi Shen	Mu Li Fen
Bai Tou Weng	Du Huo	Huai Hua Mi	Mu Tong
Bai Xian Pi	Du Zhong	Huang Bai	Mu Xiang
Bai Zhi	Du Zhong Ye	Huang Jing	Nan Sha Shen
Bai Zhu	E Jiao	Huang Lian	Niu Bang Zi
Bai Zi Ren	E Zhu	Huang Qi	Niu Xi
Ban Lan Gen	Fan Xie Ye	Huang Qin	Nu Zhen Zi
Ban Xia	Fang Feng	Huo Ma Ren	Ou Jie
Bei Xie	Fang Ji	Huo Xiang	Ou Jie Tan
Bi Ba	Fa Shou	Jing Jie	Pang Da Hai
Bian Dou	Fu Hai Shi	Ji Guan Hua	Pj Pa Ye
Bian Xu	Fu Ling	Ji Nei Jin	Pu Gong Ying
Bie Jia	Fu Ling (curled)	Ji Xue Teng	Pu Huang
Bing Lang	Fu Ling Pi	Jiang Can	Qian Cao Gen
Bing Pian	Fu Pen Zi	Jiang Huang	Qian Hu
Bo He	Fu Shen	Jie Geng	Qian Nian Jian
Bu Gu Zhi	Fu Xiao Mai	Jin Qian Cao	Qian Niu Zi
Cang Er Zi	Gan Cao Shen	Jin Yin Hua	Qian Shi
Cang Zhu	Gan Cao Zhi	Jing Ying Zi	Qiang Huo
Ce Bai Ye	Gan Jiang	Ju Hua	Qin Jiao
Chai Hu	Gan Sui	Jue Ming Zi	Qing Hao
ChanTui	Gao Ben	Ku Lian Gen Pi	Qing Pi
Che Qian Cao	Gao Liang Jiang	Ku Shen	Qing Tian Kui
Che Qian Zi	Ge Gen	Kuan Dong Hua	Qing Xian Zi
Chen Pi	Gou Ji	Kun Bu	Qu Mai
Chen Xiang	Gou Qi Zi	Lai Fu Zi	Quan Xie
Chi Shao	Gou Teng	Lian Qiao	Ren Dong Teng
Chi Xiao Dou	Gu Sui Bu	Lian Zi	Ren Shen
Chuan Bei Mu	Gu Ya	Lian Zi Xin	Ren Shen (Korean)
Chuan Bei Xie	Gua Lou	Liu Huang	Ren Shen Xu
Chuan Lian Zi	Gua Lou Pi	Liu Ji Nu	Rou Dou Ko
Chuan Niu Xie	Gua Lou Ren	Long Dan Cao	Rou Gui
Chuan Shan Long	Gui Ban	Long Gu	Rou Kong Rong
Chuan Wu	Gui Zhi	Long Yan Rou	Ru Xiang
Chuan Wu Pian	Hai Feng Teng	Lu Gen	San Leng
Chuan Xiong	Hai Piao Xiao	Lu Hui	San Qi
Ci Shi	Hai Tong Pi	Lu Lu Tong	Sang Bai Pi

## Appendix A (continued) – Herbs and Tea Pills at DIAOM

### Raw Herbs (continued)

Sang Ji Sheng	Tong Cao	Ze Lan
Sang Shen	Tu Fu Ling	Ze Xie
Sang Ye	Tu Si Zi	Zhang Nao
Sang Zhi	Wang Bu Liu Xiang	Zhe Bei Mu
Sha Ren	Wei Ling Xian	Zhen Zu
Sha Yuan Zi	Wu Gong	Zhi Ke
Shan Yao	Wu Jia Pi	Zhi Mu
Shan Zha	Wu Ling Zhi	Zhi Nan Xing
Shan Zhu Yu	Wu Mei	Zhi Shi
Shang Lu	Wu Wei Zi	Zhi Zi
She Gan	Wu Yao	Zhu Ru
She Tui	Wu Zhu Yu	Zi Cao
Shen Qin Cao	Xi Xin	Zi Cao Wu
Shen Qu	Xi Yang Shen	Zi Hua Di Ding
Sheng Chuang Zi	Xia Ku Cao	Zi Ran Tong
Sheng Ma	Xian He Cao	Zi Su Ye
Shi Chang Pu	Xian Mao	Zi Su Zi
Shi Gao	Xiang Fu	Zi Wan
Shi Gao (powder)	Xiao Hui Xiang	Zi Zhu
Shi Hu	Xie Bai	Zhu Ling
Shi Jian Chuang	Xin Yi Ha	
Shi Jue Ming	Xing Ren	
Shi Wei	Xu Duan	
Shu Di Huang	Xuan Fu Hua	
Shu Fu Zi	Xuan Shen	
Shui Niu Jiao	Ya Dan Zi	
Shui Zhi	Yan Hu Suo	
Si Gua Luo	Ye Jiao Teng	
Song Jie	Ye Ju Hua	
Song Xian	Yi Mu Cao	
Suan Zao Ren	Yi Yi Ren	
Suo Yang	Yi Zhi Ren	
Tai Zi Shen	Yin Chen Hao	
Tao Ren	Ying Yang Huo	
Tian Hua Fen	Yuan Zhi	
Tian Ma	Yu Jin	
Tian Nan Xing	Yu Li Ren	
Tian Qi	Yu Xing Cao	
Ting Li Zi	Yu Zhu	
	Yuan Hua	

## Appendix A (continued) – Herbs and Tea Pills at DIAOM

### Golden Flower Herbs

ASTRAGALUS & LIGUSTRUM FORMULA	LILY PRESERVE METAL FORMULA
ASTRAGALUS FORMULA	MING MU FORMULA
ASTRAGALUS FORMULA SYRUP	MINOR BLUEGREEN DRAGON FORMULA
BLOOD PALARE FORMULA	PEARL CREAM
BUPLEURUM & TANG KUEI FORMULA	MINOR BUPLEURUM FORMULA
BUPLEURUM D FORMULA	NOURISH ESSENCE FORMULA
CHASE WING, PENETRATE BONE FORMULA	PEACEFUL SPIRIT FORMULA
CINNAMMON & PORIA FORMULA	PERSICA AND CISTANCHES FORMULA
CINNAMMON D FORMULA	PINELLIA & MAGNOLIA BARK FORMULA
CLEMATIS & STEPHANIA FORMULA	PORIA & FENNEL FORMULA
COPTIS RELIEVE TOXICITY FORMULA	PORIA 15 FORMULA
CORYDALIS FORMULA	PUERARIA FORMULA
DUHUO & LORANTHUS FORMULA	PULSATILLA INTESTINAL FORMULA
EASE DIGESTION FORMULA	REHMANNIA & SCROPHULARIA
EIGHT IMMORTALS FORMULA	REHMANNIA COOL BLOOD FORMULA
ESSENTIAL YANG FORMULA	SALVIA TEN FORMULA
FREE & EASY WANDERER PLUS FORMULA	SAN QI TABLETS
FRITILLARIA & PINELLIA SYRUP	SEA OF QI FORMULA
GASTRODIA & UNCARIA FORMULA	SIBERIAN GINSENG TABLETS
GENERAL TONIC FORMULA	SIX GENTLEMEN FORMULA
GENTIANA DRAIN FIRE FORMULA	TANG KUEI & PEONY FORMULA
GINKGO FORMULA	TANG KUEI & SALVIA FORMULA
GINSENG & ASTRAGALUS FORMULA	TIEH TA FORMULA
GINSENG NOURISHING FORMULA	TRUE YIN FORMULA
HE SHOU WU TABLETS	TWO IMMORTALS FORMULA
HEAVENLY EMPEROR'S FORMULA	VIOLA CLEAR FIRE FORMULA
INTESTINAL FUNGUS FORMULA	WOMEN'S PRECIOUS FORMULA
JADE SCREEN & XANTHIUM FORMULA	WU HUA FORMULA
JING QI FORMULA	YIN CHIAO FORMULA
JUAN BI FORMULA	

### Other Herbs

Dragon Diet BHI  
Heel  
Ligaplex II  
Traumeel Ointment  
Black Walnut  
Vitamin A  
Huo Xiang Zheng Qi Wan  
Wood Lock  
Oriented Oil  
Colpac (small)  
Colpac (large)

## Appendix A (continued) – Herbs and Tea Pills at DIAOM

Patent Herbs	Tea Pills
Alrodeer Pill	Anmien Pen
Armadillo Counter Poison Pill	Bu Fei Teapills
Bai Zi Yang Xin Wan	Calm in the Sea of Life Teapills
Banlangen Chongji	Calm Spirit Teapills
Bao Ji Wan	Calm Stomach Teapills
Baohe Wan	Chuan Xin Lian
BHI Cold	Clean Air Teapills
BHI Cough	Clear Mountain Teapills
BHI Spasm-Pain	Clear Wind Heat Teapills
Bu Zhong Yi Qi Wan	Curing Pill
Cataract Vision-Improving Pills	Eight Righteous Teapills
Ching Fei Yi Huo Pien	Emperors Teapills
Ching Wan Hung	Five Peel Teapills
Chuan Xiong Cha Tiao Wan	Four Gentlemen Teapills
Chuang Yao Tonic	Gan Mao Ling
Crocodile Bile Pill	Great Corydalis Teapills
Da Bu Wan	Great Pulse Teapills
Da Bu Yin Wan	Great Yang Restoration Teapills
Dang Gui Su	Jade Screen Teapills
Dermocure Ointment	Jade Spring Teapills
Diet Tea	Ledebouriella Sagely Unblocks Teapills
Dragon Diet	Lidan Pian
Er Chen Wan	Llycium Rehmannia Teapills
Er long Zuo Ci Wan	Lycu-Chrysanthemum Teapills
Essential Balm	Magnolia Flower
Imperial Panax Ginseng Extract	Margari te Acne Pills
Gripp-Heel	Nei Xiao Luo Li Teapills
Guci Pian	Panta Teapills
Gui Pi Wan	Pe Min Kan Wan
Huang Lien	Pinellia Root Teapills
Huo Xiang Zhen Qi Wan	Salvia Teapills
Jiang Ya Pien	Six Flavor Teapills
Jie Geng Wan	Solitary Hermit Teapills
Jigucao Wan	Soothe Liver
Jin Gui Di Huang Wan	Stasis in the Mansion of Blood Teapills
Jin Suo Gu Jing Wan	Suan Zao Ren Teng
Kai Yeung Pil	The Snake & Dragon Teapills
Ligaplex II	You Gui Teapills
Liu Shen Shui	Zuo Gui Teapills
Long Dan Xie Gan Wan	
Luobuma Chaing Yapien	
Ma Wei Di Huang Wan	
Ming Mu Di Huang Wan	
Ming Mu Shang Ching Pien	
Nu Ke Ba Zhen Wan	
Passwan	
Pearl Cream	
Piantoutong Wan	
Placenta Compound Restorative Pills	
Po Sum On Medicated Oil	
Pro Botanixx CR-21 0 (Jiang Zhi)	
Rhematic Plaster	
Run Chang Wan	
Sai Mei An	
San Bow Soul	
San She Dan Chuan Bei Ye	
San She Tan	
Sang Chu Tablets	
Sciatica Pills	
Sea Horse Combination	
Shen Qi Da Bu Pills	
Shen Qi Wu Wei Zi Wan	
Shi Hu Ye Guang Wan	
Shilintong	
Shui De An Capsules	
Shu Gan Wan	
Superior Sore Throat Powder Spray	
Imperial Tang Kwei Gin	
Tian Ma Wan	
Tieh Ta Yao Gin	
Tiger Balm	
To Jing Wan	
Traumeel	
Wan Hua Shi Oil	
Watermelon Frost	
Wu Chi Paifeng Wan	
Wuling San	
Xiang Sha Yang Wei Wan	
Xiao Chai Hu Tang Wan	
Xiao Yao Wan	
Yudai Pills (100 pills)	
Yudai Pills (200 pills)	
Yunnan Pai Yao	
Yunnan Pai Yao (box)	
Zheng Gu Shui (large)	
Zheng Gu Shui (small)	
Zhi Bai Di Huang Wan	

**For Information on Other  
Occupational Safety and Health Concerns**

**Call NIOSH at:  
1-800-35-NIOSH (356-4674)  
or visit the NIOSH Web site at:  
[www.cdc.gov/niosh](http://www.cdc.gov/niosh)**



- Delivering on the Nation's promise:**
- **Safety and health at work for all people through research and prevention**